PLX-R18 for Post-Exposure Prevention or Treatment of Hematopoietic Syndrome of Acute Radiation Syndrome
Ionizing Radiation Exposure
Enrolment: 27 · Results not recorded
Biologic · PLX-R18 (PLX-RAD) expanded human placental stromal cells and secretome; cell therapy.
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Ionizing Radiation Exposure
Enrolment: 27 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Lethal acute radiation syndrome induced by 7.7 Gy whole body irradiation using a clinical 6-18 MeV linear accelerator
Two intramuscular PLX-RAD injections raised 21 day survival after 7.7 Gy from about 25 per cent to nearly 100 per cent, with faster regain of weight and haematopoietic recovery from day 9 onwards, associated with elevated circulating human cytokines.
Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.